Federated Hermes Inc. Acquires Shares of 339,047 Palvella Therapeutics, Inc. $PVLA

Federated Hermes Inc. acquired a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 339,047 shares of the company’s stock, valued at approximately $21,255,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. JPMorgan Chase & Co. increased its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics in the second quarter valued at about $85,000. BNP Paribas Financial Markets acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth about $104,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Palvella Therapeutics during the 2nd quarter worth about $110,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $76.69 on Friday. The company has a market capitalization of $908.01 million, a P/E ratio of -29.16 and a beta of -0.16. Palvella Therapeutics, Inc. has a 1 year low of $12.60 and a 1 year high of $114.69. The business’s 50 day simple moving average is $96.59 and its 200 day simple moving average is $72.30.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PVLA. Cantor Fitzgerald increased their price target on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Craig Hallum assumed coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 target price on the stock. Mizuho initiated coverage on Palvella Therapeutics in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $205.00 price target for the company. Canaccord Genuity Group increased their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, HC Wainwright set a $200.00 target price on Palvella Therapeutics and gave the stock a “buy” rating in a report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $158.69.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 12,906 shares of company stock worth $1,205,980 over the last three months. Corporate insiders own 20.50% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.